%0 Journal Article
%A Mack, Stephen C
%A Pajtler, Kristian
%A Chavez, Lukas
%A Okonechnikov, Konstantin
%A Bertrand, Kelsey C
%A Wang, Xiuxing
%A Erkek, Serap
%A Federation, Alexander
%A Song, Anne
%A Lee, Christine
%A Wang, Xin
%A McDonald, Laura
%A Morrow, James J
%A Saiakhova, Alina
%A Sin-Chan, Patrick
%A Wu, Qiulian
%A Michaelraj, Kulandaimanuvel Antony
%A Miller, Tyler E
%A Hubert, Christopher G
%A Ryzhova, Marina
%A Garzia, Livia
%A Donovan, Laura
%A Dombrowski, Stephen
%A Factor, Daniel C
%A Luu, Betty
%A Valentim, Claudia L L
%A Gimple, Ryan C
%A Morton, Andrew
%A Kim, Leo
%A Prager, Briana C
%A Lee, John J Y
%A Wu, Xiaochong
%A Zuccaro, Jennifer
%A Thompson, Yuan
%A Holgado, Borja L
%A Reimand, Jüri
%A Ke, Susan Q
%A Tropper, Adam
%A Lai, Sisi
%A Vijayarajah, Senthuran
%A Doan, Sylvia
%A Mahadev, Vaidehi
%A Miñan, Ana Fernandez
%A Gröbner, Susanne
%A Lienhard, Matthias
%A Zapatka, Marc
%A Huang, Zhiqin
%A Aldape, Kenneth D
%A Carcaboso, Angel M
%A Houghton, Peter J
%A Keir, Stephen T
%A Milde, Till
%A Witt, Hendrik
%A Li, Yan
%A Li, Chao-Jun
%A Bian, Xiu-Wu
%A Jones, David
%A Scott, Ian
%A Singh, Sheila K
%A Huang, Annie
%A Dirks, Peter B
%A Bouffet, Eric
%A Bradner, James E
%A Ramaswamy, Vijay
%A Jabado, Nada
%A Rutka, James T
%A Northcott, Paul A
%A Lupien, Mathieu
%A Lichter, Peter
%A Korshunov, Andrey
%A Scacheri, Peter C
%A Pfister, Stefan
%A Kool, Marcel
%A Taylor, Michael D
%A Rich, Jeremy N
%T Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
%J Nature 
%V 553
%N 7686
%@ 1476-4687
%C London [u.a.]
%I Nature Publ. Group
%M DKFZ-2018-00087
%P 101 - 105
%D 2018
%X Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective molecular targets. Intracranial ependymomas are segregated on the basis of anatomical location (supratentorial region or posterior fossa) and further divided into distinct molecular subgroups that reflect differences in the age of onset, gender predominance and response to therapy. The most common and aggressive subgroup, posterior fossa ependymoma group A (PF-EPN-A), occurs in young children and appears to lack recurrent somatic mutations. Conversely, posterior fossa ependymoma group B (PF-EPN-B) tumours display frequent large-scale copy number gains and losses but have favourable clinical outcomes. More than 70
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29258295
%R 10.1038/nature25169
%U https://inrepo02.dkfz.de/record/131790